Plasminogen activator inhibitor-1: A common denominator in obesity, diabetes and cardiovascular disease

Current Opinion in Pharmacology

Volumn 5, Issue 2 SPEC. ISS., 2005, Pages 149-154

  Taeye, Bart De ^a   Smith, L Harris ^a   Vaughan, Douglas E ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIFIBRINOLYTIC AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; METFORMIN; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE SYNTHASE INHIBITOR; ORAL ANTIDIABETIC AGENT; PENTOXIFYLLINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLASMINOGEN ACTIVATOR INHIBITOR 1 ANTAGONIST; UNCLASSIFIED DRUG;

ADIPOSE TISSUE; ARTERIOSCLEROSIS; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CORONARY ARTERY THROMBOSIS; DISEASE ASSOCIATION; DRUG TARGETING; GLUCOSE INTOLERANCE; HUMAN; HYPERTRIGLYCERIDEMIA; INFLAMMATION; INSULIN RESISTANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN SYNTHESIS; PROTEIN SYNTHESIS INHIBITION; RISK REDUCTION; SYSTEMATIC REVIEW;

EID: 15044365690     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coph.2005.01.007     Document Type: Review

References (36)

1. R.H. Eckel W.W. Barouch A.G. Ershow T.A. Pearson Report of the National Heart, Lung, and Blood Institute-National Institute of Diabetes and Digestive and Kidney Diseases Working Group on the pathophysiology of obesity-associated cardiovascular disease Circulation 105 2002 2923-2928
2. H.P. Kohler P.J. Grant Plasminogen-activator inhibitor type 1 and coronary artery disease N Engl J Med 342 2000 1792-1801
3. M. Eren C.A. Painter J.B. Atkinson P.J. Declerck D.E. Vaughan Age-dependent spontaneous coronary arterial thrombosis in transgenic mice that express a stable form of human plasminogen activator inhibitor-1 Circulation 106 2002 491-496
4. R.D. Rosenberg W.C. Aird Vascular-bed-specific hemostasis and hypercoagulable states N Engl J Med 340 1999 1555-1564
5. B.E. Sobel J. Woodcock-Mitchell D.J. Schneider R.E. Holt K. Marutsuka H. Gold Increased plasminogen activator inhibitor type 1 in coronary artery atherectomy specimens from type 2 diabetic compared with nondiabetic patients Circulation 97 1998 2213-2221
6. A. Pandolfi D. Cetrullo R. Polishuck M.M. Alberta A. Calafiore G. Pellegrini E. Vitacolonna F. Capani A. Consoli Plasminogen activator inhibitor type 1 is increased in the arterial wall of type II diabetic subjects Arterioscler Thromb Vasc Biol 21 2001 1378-1382
7. K. Kaikita J.A. Schoenhard C.A. Painter R.T. Ripley N.J. Brown A.B. Fogo D.E. Vaughan Potential roles of plasminogen activator system in coronary vascular remodeling induced by long-term nitric oxide synthase inhibition J Mol Cell Cardiol 34 2002 617-627
8. P. Angleton W.L. Chandler G. Schmer Diurnal variation of tissue-type plasminogen activator and its rapid inhibitor (PAI-1) Circulation 79 1989 101-106
9. J.A. Schoenhard M. Eren C.H. Johnson D.E. Vaughan Alternative splicing yields novel BMAL2 variants: Tissue distribution and functional characterization Am J Physiol Cell Physiol 283 2002 C103-C114
10. N.J. Brown M.A. Agirbasli G.H. Williams W.R. Litchfield D.E. Vaughan Effect of activation and inhibition of the renin-angiotensin system on plasma PAI-1 Hypertension 32 1998 965-971
11. Y.Q. Chen M. Su R.R. Walia Q. Hao J.W. Covington D.E. Vaughan Sp1 sites mediate activation of the plasminogen activator inhibitor-1 promoter by glucose in vascular smooth muscle cells J Biol Chem 273 1998 8225-8231
12. X.L. Du D. Edelstein L. Rossetti I.G. Fantus H. Goldberg F. Ziyadeh J. Wu M. Brownlee Hyperglycemia-induced mitochondrial superoxide overproduction activates the hexosamine pathway and induces plasminogen activator inhibitor-1 expression by increasing Sp1 glycosylation Proc Natl Acad Sci USA 97 2000 12222-12226
13. B. Hou M. Eren C.A. Painter J.W. Covington J.D. Dixon J.A. Schoenhard D.E. Vaughan Tumor necrosis factor alpha activates the human plasminogen activator inhibitor-1 gene through a distal nuclear factor kappaB site J Biol Chem 279 2004 18127-18136
14. C.J. Lyon R.E. Law W.A. Hsueh Minireview: Adiposity, inflammation, and atherogenesis Endocrinology 144 2003 2195-2200
15. D. Bastelica A. Mavri M. Verdierl B. Berthet I. Juhan-Vague M.C. Alessi Relationships between fibrinolytic and inflammatory parameters in human adipose tissue: Strong contribution of TNFalpha receptors to PAI-1 levels Thromb Haemost 88 2002 481-487
16. F. Samad K.T. Uysal S.M. Wiesbrock M. Pandey G.S. Hotamisligil D.J. Loskutoff Tumor necrosis factor alpha is a key component in the obesity-linked elevation of plasminogen activator inhibitor 1 Proc Natl Acad Sci USA 96 1999 6902-6907
17. D.M. Kerins Q. Hao D.E. Vaughan Angiotensin induction of PAI-1 expression in endothelial cells is mediated by the hexapeptide angiotensin IV J Clin Invest 96 1995 2515-2520
18. N.J. Brown S. Nakamura L. Ma I. Nakamura E. Donnert M. Freeman D.E. Vaughan A.B. Fogo Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo Kidney Int 58 2000 1219-1227
19. N.J. Brown S. Kumar C.A. Painter D.E. Vaughan ACE inhibition versus angiotensin type 1 receptor antagonism: Differential effects on PAI-1 over time Hypertension 40 2002 859-865
20. N.J. Brown M.A. Agirbasli G.H. Williams W.R. Litchfield D.E. Vaughan Effect of activation and inhibition of the renin-angiotensin system on plasma PAI-1 Hypertension 32 1998 965-971
21. M.C. Alessi D. Bastelica P. Morange B. Berthet I. Leduc M. Verdier O. Geel I. Juhan-Vague Plasminogen activator inhibitor 1, transforming growth factor-beta1, and BMI are closely associated in human adipose tissue during morbid obesity Diabetes 49 2000 1374-1380
22. K. Schafer K. Fujisawa S. Konstantinides D.J. Loskutoff Disruption of the plasminogen activator inhibitor 1 gene reduces the adiposity and improves the metabolic profile of genetically obese and diabetic ob/ob mice FASEB J 15 2001 1840-1842
23. L.J. Ma S.L. Mao K.L. Taylor T. Kanjanabuch Y. Guan Y. Zhang N.J. Brown L.L. Swift O.P. McGuinness D.H. Wasserman et al. Prevention of obesity and insulin resistance in mice lacking plasminogen activator inhibitor 1 Diabetes 53 2004 336-346
24. P.E. Morange H.R. Lijnen M.C. Alessi F. Kopp D. Collen I. Juhan-Vague Influence of PAI-1 on adipose tissue growth and metabolic parameters in a murine model of diet-induced obesity Arterioscler Thromb Vasc Biol 20 2000 1150-1154
25. H.R. Lijnen E. Maquoi P. Morange G. Voros B. Van Hoef F. Kopp D. Collen I. Juhan-Vague M.C. Alessi Nutritionally induced obesity is attenuated in transgenic mice overexpressing plasminogen activator inhibitor-1 Arterioscler Thromb Vasc Biol 23 2003 78-84
26. R.B. D'Agostino Jr. R.F. Hamman A.J. Karter L. Mykkanen L.E. Wagenknecht S.M. Haffner Cardiovascular disease risk factors predict the development of type 2 diabetes: The insulin resistance atherosclerosis study Diabetes Care 27 2004 2234-2240
27. A. Festa R. D'Agostino Jr. R.P. Tracy S.M. Haffner Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: The insulin resistance atherosclerosis study Diabetes 51 2002 1131-1137
28. I. Juhan-Vague P.E. Morange C. Frere M.F. Aillaud M.C. Alessi E. Hawe S. Boquist P. Tornvall J.S. Yudkin E. Tremoli et al. The plasminogen activator inhibitor-1-6754G/5G genotype influences the risk of myocardial infarction associated with elevated plasma proinsulin and insulin concentrations in men from Europe: The HIFMECH study J Thromb Haemost 1 2003 2322-2329
29. V. Schachinger M.B. Britten A.M. Zeiher Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease Circulation 101 2000 1899-1906
30. Y. Higashi S. Sasaki K. Nakagawa H. Matsuura K. Chayama T. Oshima Effect of obesity on endothelium-dependent, nitric oxide-mediated vasodilation in normotensive individuals and patients with essential hypertension Am J Hypertens 14 2001 1038-1045
31. I.L. Williams S.B. Wheatcroft A.M. Shah M.T. Kearney Obesity, atherosclerosis and the vascular endothelium: Mechanisms of reduced nitric oxide bioavailability in obese humans Int J Obes Relat Metab Disord 26 2002 754-764
32. M. Katoh K. Egashira T. Mitsui S. Chishima A. Takeshita H. Narita Angiotensin-converting enzyme inhibitor prevents plasminogen activator inhibitor-1 expression in a rat model with cardiovascular remodeling induced by chronic inhibition of nitric oxide synthesis J Mol Cell Cardiol 32 2000 73-83
33. P.J. Grant M.H. Stickland N.A. Booth C.R. Prentice Metformin causes a reduction in basal and post-venous occlusion plasminogen activator inhibitor-1 in type 2 diabetic patients Diabet Med 8 1991 361-365
34. Y.T. Kruszynska J.G. Yu J.M. Olefsky B.E. Sobel Effects of troglitazone on blood concentrations of plasminogen activator inhibitor 1 in patients with type 2 diabetes and in lean and obese normal subjects Diabetes 49 2000 633-639
35. H. Elokdah M. Abou-Gharbia J.K. Hennan G. McFarlane C.P. Mugford G. Krishnamurthy D.L. Crandall Tiplaxtinin, a novel, orally efficacious inhibitor of plasminogen activator inhibitor-1: Design, synthesis, and preclinical characterization J Med Chem 47 2004 3491-3494
36. A.D. Weisberg F. Albornoz J.P. Griffin D.L. Crandall H. Elokdah A.B. Fogo D.E. Vaughan N.J. Brown Pharmacological inhibition and genetic deficiency of plasminogen activator inhibitor-1 attenuates angiotensin II/salt-induced aortic remodeling Arterioscler Thromb Vasc Biol 25 2004 365-371